Navigation Links
NeoStem Signs Definitive Merger Agreement to Acquire Amorcyte in Equity Transaction
Date:7/14/2011

anism, releasing from bone marrow and traveling to the damaged region of the heart following an AMI. Treatment with AMR-001 involves infusion of an active population of these cells directly into a patient’s heart via an intra-coronary catheter six to eleven days after an AMI (i.e., after the “hot (inflammatory) phase”) and as such complements the body’s natural  rescue mechanism for those cells that face hypoxic stress (i.e., oxygen deprivation) as a result of an increased workload.

Unlike competitor cell therapy products being tested for cardiac repair post-AMI, NeoStem believes AMR-001 stands alone in its ability to claim all of the following attributes:

  • a confirmed mechanism of action
  • a cGMP (current good manufacturing practices) facility
  • an established dose that exceeds the threshold of biological activity
  • use of autologous cells that have no risk of rejection and are capable of integrating and providing local support, potentially for a prolonged period of time as demonstrated in pre-clinical animal experiments
  • cells that are not expanded, thereby eliminating the potential concerns associated with such expansion
  • composition of matter, methods and processes patents with long remaining life

  • To the Company's knowledge, this is the first stem cell trial in AMI ever conducted that prospectively established a significant relationship between dose and effect. NeoStem intends to enter the clinic for the start of the Phase II trial for AMR-001 no later than the  first quarter of 2012 and to commence a Phase I study in congestive heart failure in 2012.  The enrollment of this Phase II trial is estimated to complete within 12 months from start with data read-out 6 months after the last patient is treated.

    The definitive merger agreement provides for the issuance of an aggregate of 6,821,283 shares of NeoStem common stock and warrants to purchase an aggregate o
    '/>"/>

    SOURCE NeoStem, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. NeoStem Reports Positive Stem Cell Industry Research Trends From The Journal of the American Medical Association and Third Annual Stem Cell Summit
    2. China Biopharmaceuticals Holdings, Inc. Shareholders Overwhelmingly Support Merger with NeoStem, Inc., a NYSE AMEX Listed Company Trading Under Symbol NBS
    3. NeoStem Acquires China Biopharmaceuticals Holdings, Inc.; Obtains Controlling Interest in Profitable Leading Chinese Pharmaceutical Company
    4. NeoStem, Inc. Names Edward Geehr, M.D. to Board of Directors; Biotechnology Executive Brings Scientific and Business Experience in Global Operations
    5. NeoStem Announces Warrant Exercise by Principal Shareholder
    6. NeoStem, Inc. Officially Launches Adult Stem Cell Collection Center and R&D Laboratory in Cambridge, Massachusetts
    7. NeoStem Pharmaceutical Subsidiary Announces Two cGMP Lines are Now Fully Operational in New Facility
    8. NeoStem Adds Distinguished Researcher to its World-Class Scientific Advisory Board
    9. NeoStem Comments on Recent Court Ruling Blocking the Federal Governments Funding of Embryonic Stem Cell Research
    10. NeoStem and Progenitor Cell Therapy Announce Entry Into Merger Agreement
    11. NeoStem to Present at Cell Therapy Industry Summit to be held on November 3-5, 2010 in Carlsbad, California
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/1/2015)... -- According to a new market research ... (Calcium Phosphate, Lipofection, Dendrimers), Physical (Electroporation, Nucleofection), Viral), by ... to 2020", published by MarketsandMarkets, the Transfection Reagents and ... by 2020 with a CAGR of 7.2% from 2014 ... ables and 33 F igures ...
    (Date:7/1/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/nk3569/future_horizons ... "Future Horizons and Growth Strategies in the European ... Forecasts" report to their offering. ... Blood Banking Market 2015 is a new five-countrystrategic ... and potential market entrants identify and evaluate emerging ...
    (Date:7/1/2015)... MARLBOROUGH, Mass. , July 1, 2015 Boston ... call discussing financial results and business highlights for the second ... at 8 a.m. ET. The call will be ... officer, and Dan Brennan , executive vice president and ... conference call will be available via the Boston Scientific website. ...
    Breaking Medicine Technology:Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 2Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 3Transfection Reagents and Equipment Market Worth $957.9 Million by 2020 4European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3Boston Scientific To Webcast Second Quarter 2015 Earnings Call On July 23 2
    ... TechniScan (OTC Bulletin Board: TSNI ), a ... an automated 3D breast ultrasound imaging system, announced today that ... with Austin, Texas-based Womens3D. These agreements follow ... January 2011 in which they agreed to jointly develop a ...
    ... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... company,s president and chief executive officer, is scheduled ... Markets Healthcare ConferenceWednesday, March 2, 20119:00 a.m. Eastern ... Health Care Conference Tuesday, March 8, 201111:00 a.m. ...
    Cached Medicine Technology:Breast Imaging Company, TechniScan, Signs Manufacturing Agreement With Texas Company 2
    (Date:7/1/2015)... ... 01, 2015 , ... After conducting a nationwide executive ... Medical Center in Oceanside, Calif., has hired Cheryle Bernard-Shaw as chief compliance ... adaptation efforts and growing a focus on risk management, Bernard-Shaw will assume her ...
    (Date:7/1/2015)... ... ... Incentivizing the use of generic drugs has been an easy way for plans ... off the prices for the brand-name products. But now that generics are experiencing record ... these high-cost generic drugs. The July issue of Atlantic Information Services, Inc.’s (AIS) The ...
    (Date:7/1/2015)... ... 01, 2015 , ... Northbound Treatment Services announced today that ... , Emily originally entered the behavioral healthcare industry as an academic director ... curriculum for clients to engage in their educational journey while in treatment. In ...
    (Date:7/1/2015)... ... ... Thule Atmos X4 offers protection with minimal bulk. At the Thule Test Center™, ... Due to its Bi-ComponentArmor and ShockStop corners, it passed Thule’s 2 meter drop test, ... The Thule Atmos X4 has also been designed with function in mind. The ...
    (Date:7/1/2015)... Raton, FL (PRWEB) , ... July 01, 2015 , ... ... wide range of nutritional and beauty products, recently attended the 2015 ECRM Diet, Vitamin ... big-time connections in the retail industry. The ECRM trade show allows companies ...
    Breaking Medicine News(10 mins):Health News:Tri-City Medical Center Hires New Chief Compliance Officer 2Health News:Tri-City Medical Center Hires New Chief Compliance Officer 3Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 2Health News:Blues Execs Share Strategies for Managing Generic Drug Inflation in AIS Newsletter 3Health News:Northbound Treatment Services Welcomes Emily Orrick as Director of Referral Relations 2Health News:NPI Meets With Top Retail Figures at ECRM Conference 2
    ... , THURSDAY, Sept. 15 (HealthDay News) -- Children typically don,t die ... Thursday that 115 kids younger than 18 died from flu-related causes ... many of the deaths could have been prevented if the children ... U.S. Centers for Disease Control and Prevention. , , ...
    ... protein linked to cell division and migration and tied to ... high levels in breast cancer specimens and cell lines. The ... in breast cancer cells than in normal breast cells. ... findings and others in a paper now online in the ...
    ... News) -- Experts around the world have issued a call ... A group of international medical bodies said physicians can ... and it also urged governments to take action and address ... in preventable and premature disease, affecting 76 million people globally. ...
    ... Clinic have received a grant from the National Institutes of ... test that conclusively identifies concussions in college football players. ... after a game searches for a biomarker known as ... in an athlete,s blood. Damir Janigro, Ph.D., and Nicola ...
    ... -- Not enough children and teens drink low-fat milk, a ... Prevention reveals. Drinking milk is important for children,s bone ... the calcium, vitamin D and other nutrients found in milk, ... milk products to avoid unnecessary fat and calories. ...
    ... In order to better prevent blood clots, the drugs ... acute ischaemia of the heart muscle, in addition to ... Efficiency in Health Care (IQWiG) has now investigated whether, ... coronary intervention (PCI), the combination of prasugrel plus ASA ...
    Cached Medicine News:Health News:Flu Killed 115 Children Last Season: CDC 2Health News:Flu Killed 115 Children Last Season: CDC 3Health News:Study finds protein critical to breast cancer cell proliferation, migration 2Health News:Doctors Urged to Lead Battle Against Alcohol Abuse 2Health News:Cleveland Clinic researchers awarded NIH grant to study concussion-identifying blood test 2Health News:Cleveland Clinic researchers awarded NIH grant to study concussion-identifying blood test 3Health News:Not Enough Kids Drink Low-Fat Milk, U.S. Study Finds 2Health News:Prasugrel: Indications of an additional benefit for some patients, but also of greater harm 2Health News:Prasugrel: Indications of an additional benefit for some patients, but also of greater harm 3Health News:Prasugrel: Indications of an additional benefit for some patients, but also of greater harm 4
    For the qualitative detection of IgG/IgM antibodies to B. burgdorferi...
    ... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... with maximum comfort, SheerVision loupes are ... worldwide. Make both a professional and ...
    ... surgical-quality loupes available at manufacturer-direct ... innovative optical design, combining superior quality ... with maximum comfort, SheerVision loupes are ... worldwide. Make both a professional and ...
    ... the first manufacturer to offer through-the-lens ... wearer. These next generation loupes feature ... ultra-lightweight design, and are multi-coated lens ... With SheerVision's proprietary SureFit system - ...
    Medicine Products: